Jain Neha, Roychaudhury Arkaprava, Kim JunHyuk, Dixit Ruchi, Sonawane Prasad M, Iwaoka Michio, Kim Cheol-Hee, Nimse Satish Balasaheb, Churchill David G
Department of Chemistry, Molecular Logic Gate Laboratory, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
Department of Biology, Chungnam National University, Daejeon, 34134, Republic of Korea.
Eur J Med Chem. 2025 Oct 15;296:117836. doi: 10.1016/j.ejmech.2025.117836. Epub 2025 Jun 4.
Theranostics are crucial in both cancer diagnosis and targeted drug delivery, as they enable the simultaneous detection and treatment of disease within a single molecular or conjugated platform. However, theranostics is still facing challenges like real-time tracking for "where" prodrugs are activated in vivo, which poses a significant problem for molecule development. Organ-specific action to inspire the creation of innovative disease-curing technologies that are both accurate and efficient is still an underestimated task. We herein showcase the novel serendipitous gallbladder-targeting indole-based prodrug Indo-Gem for precise imaging-guided cancer therapy. Indo-Gem was prepared by an indole-malononitrile (dye) moiety, attached to the selected parent drug Gemcitabine via a disulfide cleavable linker. Indo-Gem is triggered by DTT with 27-fold fluorescent enhancement at pH 7.4, registering within 21 min. Unlike the most ignored adverse effects in prodrug activation, this indole-based dye targeting in a specific organ region of a zebrafish model via a combination of imaging ability and drug release. This is the first case that employs an indole-based moiety in prodrug design without any use of targeting ligands; the profound success of Indo-Gem and the well-defined mechanism suggest that the indole might serve as a scaffold to create novel therapeutic prodrugs with improved drug potency in future drug development.
诊疗一体化在癌症诊断和靶向给药中都至关重要,因为它们能够在单个分子或共轭平台上同时实现疾病的检测和治疗。然而,诊疗一体化仍面临挑战,比如对体内前药“何处”被激活进行实时追踪,这对分子开发构成了重大问题。激发创新的、准确且高效的疾病治愈技术的器官特异性作用仍然是一项被低估的任务。我们在此展示了新型的、意外发现的胆囊靶向吲哚基前药Indo-Gem,用于精确成像引导的癌症治疗。Indo-Gem由吲哚-丙二腈(染料)部分通过可被二硫键裂解的连接子连接到选定的母体药物吉西他滨制备而成。Indo-Gem在pH 7.4条件下由二硫苏糖醇触发,荧光增强27倍,在21分钟内即可显色。与前药激活中最常被忽视的不良反应不同,这种基于吲哚的染料通过成像能力和药物释放的结合,在斑马鱼模型的特定器官区域实现靶向。这是首例在不使用任何靶向配体的情况下,在药物前体设计中采用基于吲哚部分的案例;Indo-Gem的巨大成功以及明确的作用机制表明,吲哚可能作为一种支架,在未来药物开发中用于创造具有更高药物效力的新型治疗性前药。